Biotech Values

[ghmm]

ALTU:

The (major) problem I see is with their stubbornness to reduce cash burn they've quickly removed their odds of getting to approval with the drug on their own. Don't forget the safety study will only conclude late q1/early q2 of next year so they won't file till mid-late '09 (I doubt mid with their history but I think that was their claim). If I heard right on the quarterly call they are basically looking to sell some/all of Trizytek anyway.